Stem Cell Quantification In Peripheral Blood After Hyperbaric Oxygen Therapy Treatments

Restorix Research Institute, LLLP

Status: Unknown

Conditions: Changes in Peripheral Blood Population Numbers and Type.

Treatments: Other: Hyperbaric Oxygen Treatment

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01740908

RF-STCELL-2012 (Other Grant/Funding Number)

RRI-2012-05-STCELL-001

Details and patient eligibility

About

This is an observational research study whose purposes are to see the effects of repeated hyperbaric oxygen therapy treatments on the levels of stem/progenitor cells in peripheral circulating blood following five days of treatment, 90 minutes per day at 2.0 atmospheres absolute in 100% USP Grade Oxygen. Hyperbaric oxygen has a greater oxygen concentration than air at sea level. In this research, the concentration of oxygen will be twice the level of oxygen at sea level.

Enrollment: 8 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Patients recruited will be healthy volunteers with no current, ongoing infection or chronic disease.

Exclusion criteria

We will exclude or delay the treatment if our patients have an active lung infection, develops cancer, if the patient cannot undergo pressurization/ depressurization because of eustachian-tube dysfunction and confinement anxiety. Any patient that cannot breathe without a respirator will be excluded.

Trial design

8 participants in 2 patient groups

Hyperbaric Oxygen Treatment

Description:

Six healthy adult individuals (18-65 yrs), with no current, ongoing infection or chronic disease will be recruited for this study. Treatment study subjects will undergo a daily exposure to 2.0 ATA, 100% Oxygen for 90 minutes over 5 days.

Treatment:

Other: Hyperbaric Oxygen Treatment

Baseline

Description:

Two healthy study subjects with no current, ongoing infection or chronic disease will be rectuited to serve as a baseline group. Study subjects will not be exposed to HBO, but will have blood drawn at the same time as the treatment group.